OncoMatch/Clinical Trials/NCT06829459
A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs
Is NCT06829459 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Glumetinib and Osimertinib mesylate for non-small cell lung cancer.
Treatment: Glumetinib · Osimertinib mesylate · Pemetrexed · Cisplatin or carboplatin — The is a randomized, controlled, open-label Phase III clinical study to evaluate the efficacy and safety of glumetinib combined with osimertinib mesylate versus platinum-based doublet chemotherapy in non-small cell lung cancer( NSCLC) patients with MET amplification and/or overexpression after resistance to EGFR-TKIs.. Approximately 350 NSCLC patients with MET amplification and/or overexpression after previous treatment with EGFR-TKIs are planned to be enrolled. After patients sign the informed consent form (ICF), those who are eligible for enrollment after screening examinations will be randomized to the investigational group or the control group in a 1:1 ratio by the central randomization system (IWRS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR sensitizing mutation
Required: MET amplification
Required: MET overexpression (ihc: 3+, ≥ 90%)
Excluded: ALK fusion
Excluded: EGFR t790m
Excluded: ROS1 fusion
Disease stage
Required: Stage IIIB, IIIC, IV
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (gefitinib, erlotinib, icotinib, afatinib, dacomitinib, osimertinib) — first-, second- or third-generation EGFR-TKIs
Patients who have experienced documented imaging PD after treatment with first-, second- or third-generation EGFR-TKIs (gefitinib, erlotinib, icotinib, afatinib, dacomitinib, osimertinib, etc.); patients who have received prior adjuvant EGFR-TKI treatment after radical surgery may be enrolled if they have had PD within 6 months after the last dose of EGFR-TKIs.
Cannot have received: targeted MET drugs
Patients with prior treatment with targeted MET drugs
Cannot have received: systemic anti-tumor therapy (including chemotherapy and immunotherapy) for advanced NSCLC other than EGFR-TKIs
Patients with prior systemic anti-tumor therapy (including chemotherapy and immunotherapy) for advanced NSCLC other than EGFR-TKIs
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify